CD150/SLAMF1 as a new potential target for anti-tumor therapy / S. P. Sidorenko [et al.] // Experimental Oncology. - 2017. - Том 39, N 1. - P90-91 MeSH-main: НОВООБРАЗОВАНИЯ -- NEOPLASMS (лекарственная терапия, терапия) ПРОТИВООПУХОЛЕВЫЕ СРЕДСТВА -- ANTINEOPLASTIC AGENTS Annotation: CD150/SLAMF1 is a prototype member of SLAM family within the immunoglobulin superfamily of surface receptors that are widely expressed on cells within hematopoietic system. Six of nine SLAMF receptors have a paired unique immunoreceptor tyrosine-based switch motif (ITSM) that serves as a docking site for SH2-containing proteins. In T and B lymphocytes, natural killer cells, macrophages and dendritic cells CD150 is a co-receptor molecule that mediates different signal transduction pathways depending on the availability of downstream signaling elements, especially, the adaptor protein SH2D1A/SAP. Due to highly glycosylated and sialylated extracellular Ig domains, CD150 is involved in homotypic interactions and could be considered as a pattern-recognizing receptor. It is a major entry receptor for several Morbilliviruses, including measles virus, and also a bacterial sensor that control the killing of Gram-negative bacteria. Functionally it serves as a bridge between innate and adaptive immunity Additional Access Points: Sidorenko, S.P. Romanets-Korbut, O. Gordiienko, I. Kovalevska, L. Shlapatska, L. There are no free copies